Loading...
•
Jun 30, 2021
NextCure Q2 2021 Earnings Report
Reported second quarter 2021 financial results and provided a business update.
Key Takeaways
NextCure reported second quarter 2021 financial results and provided a business update, highlighting progress across its clinical programs, including enhancements to the NC318 Phase 2 monotherapy trial and the initiation of clinical development for NC762.
Made notable progress across all clinical programs.
Enhanced the ongoing NC318 Phase 2 monotherapy trial.
Resumed enrolling non-small cell lung cancer (NSCLC) adenocarcinoma patients in the ongoing NC318 monotherapy trial.
Initiated clinical development of NC762 targeting B7-H4.
Forward Guidance
Based on its current research and development plans, NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...